Use access key #2 to skip to page content.
$26.00 1.13 (4.54%)
7/8/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

1

Avatar MLErik (79.67) Submitted: 12/01/07 3:07 AM : Outperform Start Price: $37.88 AMLN Score: -17.20

Nearing support at $36, the data from the last drug trials was positive. The diabetes market is huge and Amlyin is extremely attractive to the bigger names that have no growth left (PFE)

Report this Post Replies: 0 | Reply

Featured Broker Partners